Page 15 - CIBERER-2016-cast

900
800
700
600
500
400
300
200
100
0
EVOLUCIÓN DE PUBLICACIONES CIBERER 2010-2016
2010
2011
2012
2013
2014
2015
2016
No TOTAL
Q1 D1
Publicaciones más relevantes del CIBERER durante 2016 según factor de impacto
Publicación
Factor Impacto
Latorre-Pellicer A., Moreno-Loshuertos R., Lechuga-Vieco A.V., Sanchez-Cabo F., Torroja C., Acin-Perez R. et al. Mitochondrial and nuclear DNA matching shapes metabolism and healthy ageing. Nature. 2016;535(7613):561-565.
38,891
Dunning A.M., Michailidou K., Kuchenbaecker K.B., Thompson D., French J.D., Beesley J. et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics. 2016;48(4):374-38.
38,138
Zhou W., Machiela M.J., Freedman N.D., Rothman N., Malats N., Dagnall C. et al. Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nature Genetics. 2016;48(5):563-568.
37,369
Kenna K.P., Van Doormaal P.T.C., Dekker A.M., Ticozzi N., Kenna B.J., Diekstra F.P. et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics. 2016;48(9):1037- 1042.
34,661
Van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics. 2016;48(9):1043-1048.
34,090
de la Torre R., de Sola S., Hernandez G., Farre M., Pujol J., Rodriguez J. et al. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 2016;15(8):801-810.
34,090
ER
organización 15